|
rs2282794
|
FGF1;SPRY4-AS1
|
Attention deficit hyperactivity disorder
|
|
0.010 |
GeneticVariation |
BEFREE |
SNPs rs362990-<i>SNAP25</i> (T allele; <i>p</i> = 2.46 × 10<sup>-4</sup>), rs2282794-<i>FGF1</i> (A allele; <i>p</i> = 1.33 × 10<sup>-2</sup>), rs2122642-<i>ADGRL3</i> (C allele, <i>p</i> = 3.5 × 10<sup>-2</sup>), and <i>ADGRL3</i> haplotype CCC (markers rs1565902-rs10001410-rs2122642, OR = 1.74, <i>P</i><sub>permuted</sub> = 0.021) were significantly associated with ADHD.
|
31426340 |
2019 |
|
rs34011
|
FGF1;SPRY4-AS1
|
Alzheimer's Disease
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that the genotype distribution of rs34011 was significantly different between AD and control group (χ(2) = 9.048, df = 2, P = 0.011).
|
24464990 |
2014 |
|
rs7727832
|
FGF1;SPRY4-AS1
|
Carcinoma, Ovarian Epithelial
|
|
0.010 |
GeneticVariation |
BEFREE |
In particular, FGF1 [fibroblast growth factor 1 (acidic)] SNP rs7727832 showed the most significant association with ovarian cancer (odds ratio, 2.27; 95% CI, 1.31-3.95).
|
24146310 |
2014 |
|
rs7727832
|
FGF1;SPRY4-AS1
|
Malignant neoplasm of ovary
|
|
0.010 |
GeneticVariation |
BEFREE |
In particular, FGF1 [fibroblast growth factor 1 (acidic)] SNP rs7727832 showed the most significant association with ovarian cancer (odds ratio, 2.27; 95% CI, 1.31-3.95).
|
24146310 |
2014 |
|
rs7727832
|
FGF1;SPRY4-AS1
|
ovarian neoplasm
|
|
0.010 |
GeneticVariation |
BEFREE |
In particular, FGF1 [fibroblast growth factor 1 (acidic)] SNP rs7727832 showed the most significant association with ovarian cancer (odds ratio, 2.27; 95% CI, 1.31-3.95).
|
24146310 |
2014 |
|
rs250108
|
FGF1;SPRY4-AS1
|
estrogen receptor-negative breast cancer
|
|
0.010 |
GeneticVariation |
BEFREE |
In contrast, FGF1 rs250108 was significantly associated with the risk of ER-negative breast cancer (OR (95% CI) = 1.68 (1.20-2.35) for CT + TT vs. CC genotype) but not ER-positive breast cancer.
|
23143756 |
2013 |
|
rs250108
|
FGF1;SPRY4-AS1
|
Oestrogen receptor positive breast cancer
|
|
0.010 |
GeneticVariation |
BEFREE |
Our findings show a suggestively stronger association between FGFR2 rs2981582 and ER-positive breast cancer risk and suggest a greater association of FGF1 rs250108 and RBFOX2 rs2051579 with ER-negative compared to ER-positive breast cancer.
|
23143756 |
2013 |
|
rs451275
|
SPRY4-AS1
|
Post-Traumatic Stress Disorder
|
|
0.010 |
GeneticVariation |
BEFREE |
Haplotype analysis revealed that the C/G haplotype (rs451275/rs386231) was significantly associated with PTSD (p=0.001).
|
23146198 |
2013 |
|
rs152524
|
FGF1;SPRY4-AS1
|
Hypertensive disease
|
|
0.010 |
GeneticVariation |
BEFREE |
Single and multilocus family-based analysis revealed that genetic variation within FGF1 haploblock 1 was associated with hypertension and identified a common intronic single nucleotide polymorphism, rs152524, as the major driver of this association (P=0.0026).
|
17909102 |
2007 |
|
rs10065321
|
SPRY4-AS1
|
Waist-Hip Ratio
|
|
0.700 |
GeneticVariation |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
rs10477176
|
SPRY4-AS1
|
Systolic Pressure
|
A |
0.700 |
GeneticVariation |
GWASCAT |
Trans-ethnic association study of blood pressure determinants in over 750,000 individuals.
|
30578418 |
2019 |
|
rs153662
|
SPRY4-AS1
|
Body Height
|
|
0.700 |
GeneticVariation |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
rs2070715
|
FGF1;SPRY4-AS1
|
AIDS, PROGRESSION TO
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial.
|
31219150 |
2019 |
|
rs2070715
|
FGF1;SPRY4-AS1
|
Viral Load result
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial.
|
31219150 |
2019 |
|
rs2070715
|
FGF1;SPRY4-AS1
|
ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial.
|
31219150 |
2019 |
|
rs2070715
|
FGF1;SPRY4-AS1
|
HIV-1, RESISTANCE TO
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial.
|
31219150 |
2019 |
|
rs2070715
|
FGF1;SPRY4-AS1
|
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial.
|
31219150 |
2019 |
|
rs250100
|
FGF1;SPRY4-AS1
|
Body Height
|
|
0.700 |
GeneticVariation |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
rs253443
|
SPRY4-AS1
|
Red cell distribution width determination
|
|
0.700 |
GeneticVariation |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
rs253443
|
SPRY4-AS1
|
RDW - Red blood cell distribution width result
|
|
0.700 |
GeneticVariation |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
rs34000
|
FGF1;SPRY4-AS1
|
Waist-Hip Ratio
|
T |
0.700 |
GeneticVariation |
GWASCAT |
Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry.
|
30239722 |
2019 |
|
rs34000
|
FGF1;SPRY4-AS1
|
Waist-Hip Ratio
|
|
0.700 |
GeneticVariation |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
rs34427173
|
SPRY4-AS1
|
Body Height
|
|
0.700 |
GeneticVariation |
GWASCAT |
Characterizing rare and low-frequency height-associated variants in the Japanese population.
|
31562340 |
2019 |
|
rs76271629
|
SPRY4-AS1
|
Systolic Pressure
|
|
0.700 |
GeneticVariation |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
rs1650911
|
SPRY4-AS1
|
Systolic Pressure
|
G |
0.700 |
GeneticVariation |
GWASCAT |
Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits.
|
30224653 |
2018 |